Pembrolizumab plus concurrent chemoradiotherapy extends survival in locally advanced cervical cancer
New study findings support this treatment strategy as a new standard of care for patients with high-risk, locally advanced cervical cancer
Towards a brighter future for gynaecological cancers
Improvements in the understanding of molecular mechanisms, together with a greater focus on prevention, are key elements to countering gynaecological malignancies
PD-1 inhibition plus chemoradiotherapy is effective across ethnicities in locally advanced cervical cancer
However, studies highlight cost as an obstacle to widespread accessibility in some countries
Disappointing early results for niraparib plus dostarlimab in the treatment of relapsed endometrial or ovarian carcinosarcomas
The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination
Dostarlimab shows preliminary but durable activity across multiple cancers
Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment
Adding atezolizumab to bevacizumab and chemotherapy improves outcomes in metastatic cervical cancer
Results from the BEATcc study strongly support the use of first-line combination therapy for R/M CC in all patients
Induction chemotherapy before CRT improves outcomes in locally advanced cervical cancer
Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease
PROs support dostarlimab plus chemotherapy as a new standard of care in endometrial cancer
Data from selected patients in the RUBY trial show improvements in QoL domains over the course of treatment and benefits compared with placebo
Checkpoint inhibition improves outcomes in high-risk, locally advanced cervical cancer
In the KEYNOTE-A18 study, the combination of pembrolizumab and concurrent chemoradiotherapy significantly improved progression-free survival
First-line immunotherapy prolongs survival in advanced or recurrent endometrial cancer
Results from the RUBY trial show improvements both in progression-free survival and overall survival in patients treated with dostarlimab plus standard chemotherapy, indicating a new standard of care